Earlier-Line CAR T–Cell Therapy Integration: Predictable Delivery Through Clinical and Operational Alignment

This three-part video series explores the evolving role of CAR T–cell therapy in earlier lines of treatment, focusing on the operational and clinical factors that influence successful integration. Through peer-to-peer dialogue between Sarah Nikiforow, MD, PhD, and Kelly Tomlinson, DNP, RN, NEA-BC, the program examines how manufacturing timelines, bridging strategies, and multidisciplinary coordination intersect to shape real-world delivery. Emphasis is placed on improving predictability, strengthening workflow alignment, and supporting treatment centers in building reliable, scalable approaches to CAR T–cell delivery. 

Chapter 1: Vein-to-Vein Time: What Drives Operational Predictability

This chapter examines the key drivers of operational predictability across the vein-to-vein interval in CAR T–cell therapy. Through expert discussion, it highlights how manufacturing coordination, insurance authorization, and internal workflow handoffs can introduce delays that impact patient outcomes. Emphasis is placed on proactive, multidisciplinary planning to reduce variability and support timely infusion.

Chapter 2: Clinical Evidence and Operational Implications 

This chapter reviews the clinical evidence supporting earlier-line use of CAR T–cell therapy and explores its implications for referral timing and care coordination. Faculty discuss how evolving data are shifting treatment pathways and necessitating more proactive, structured collaboration between referring physicians and treatment centers. Emphasis is placed on aligning referral processes, bridging strategies, and pre-apheresis readiness to support timely and effective CAR T–cell delivery.

Chapter 3: Building Scalable Programs: Multidisciplinary Coordination, Outpatient Readiness, and Institutional Capacity 

This chapter explores the multidisciplinary infrastructure required to deliver CAR T–cell therapy safely and at scale. Faculty discuss the roles of extended care teams, the requirements for inpatient monitoring and outpatient readiness, and the systems needed to support coordinated, timely care. Emphasis is placed on building reproducible workflows and institutional capacity to ensure consistent and reliable CAR T–cell delivery as utilization expands.